Companies · Software / Tech
Austin · Software / Tech · refined from filed group “Other Health Care”
Diligence memoA one-page analyst read on NanoMedical Systems Inc — recommendation, valuation, rhythm, risks.→NanoMedical Systems Inc looks under-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the technology sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
NanoMedical Systems Inc is one of 3920 Software / Tech companies tracked from Austin. By capital raised it ranks mid-pack (ahead of 61% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the technology sector profile. Directional, not a quoted figure.
Benchmarked against 3920 companies in Software / Tech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 61% of sector peers (real $). Modeled value above 39% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #138 of 145.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Akoustis Technologies, Inc. | Series A | $55.1M | $416.1M | 2.49× |
| O(1) Labs, LLC | Series A | $15.0M | $416.1M | 2.49× |
| Canvas Technology, Inc. | Series A | $15.0M | $416.1M | 2.49× |
| Radiance Technologies, Inc. | Series A | $14.7M | $407.6M | 2.44× |
| Imagen Technologies, Inc. | Series A | $19.3M | $397.3M | 2.38× |
| Orchestra Software, Inc. | Series A | $14.0M | $389.5M | 2.33× |
| SportsMEDIA Technology Corp | Series A | $26.3M | $384.1M | 2.30× |
| Eden Technologies Inc. | Series A | $14.5M | $369.3M | 2.21× |
| Dharma Platform, Inc. | Series A | $13.0M | $361.4M | 2.16× |
| Quotient Technology Inc. | Series A | $14.0M | $360.6M | 2.16× |
| Emogi Technologies, Inc. | Series A | $15.3M | $354.5M | 2.12× |
| Breathe Technologies Inc | Series A | $20.0M | $353.7M | 2.12× |
| NanoMedical Systems Inc this company | Series A | $7.2M | $20.9M | 0.13× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $2.3M | 2012-12-06 | $11.6M | $79.1M | 85% |
| Seed | $1.7M | 2012-12-06 | $8.5M | $57.9M | 85% |
| Series A | $4.1M | 2017-04-27 | $18.8M | $114.6M | 90% |
| Series A | $753K | 2018-05-14 | $3.4M | $20.9M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Jeffrey H Margolis | — | 1 other | 2017-04 |
| William H. Cunningham | — | 1 other | 2012-12 |
| Yashvinder Sabharwal | — | 1 other | 2017-04 |
| Audre H. Rapoport | — | — | 2012-12 |
| Charles H. Mullins | — | — | 2012-12 |
| David D. Saathoff | — | — | 2012-12 |
| Gene D. Betts | — | — | 2017-04 |
| Mario H. Reimers | — | — | 2017-04 |
| Mauro K. Ferrari | — | — | 2012-12 |
| Michael H. Matula | — | — | 2012-12 |
| Peter H. Hutt | — | — | 2012-12 |
| Randal Goodall | — | — | 2017-04 |
| Randal K. Goodall | — | — | 2012-12 |
NanoMedical Systems Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| CherryCircle Software, Inc. | Software / Tech | Series A | $32.4M | $52.0M | network1 shared operator · same sector · same stage |
| Adelphi Data, Inc. | Software / Tech | Series A | $7.1M | $24.6M | same sector · same stage |
| Daro Technologies Inc. | Software / Tech | Series A | $7.4M | $22.5M | same sector · same stage |
| Even Labs Inc. | Software / Tech | Series A | $7.5M | $17.2M | same sector · same stage |
| Terranova Systems Inc. | Software / Tech | Series A | $6.8M | $23.1M | same sector · same stage |
| Steric Systems Inc. | Software / Tech | Series A | $6.8M | $23.1M | same sector · same stage |
| Tenbin Labs, Inc. | Software / Tech | Series A | $6.8M | $24.4M | same sector · same stage |
| Kaamel Technology Inc | Software / Tech | Series A | $7.7M | $23.3M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| NanoHive Medical LLC | Healthtech | Seed | $33.1M | 87% |
| NanoCare Health Services Cayman Pvt. Ltd. | Healthtech | Series A | $203.2M | 85% |
| Nanosphere Health Sciences Inc. | Healthtech | Series B | $579.8M | 85% |
| Nanox Imaging plc. | Other Health Care | Series A | $22.3M | 83% |
| Nanospectra Biosciences Inc | Biotech / Pharma | Series A | $58.8M | 83% |
| SomnoMed Technologies Inc. | Software / Tech | Pre-Seed | $3.7M | 83% |
| Polyamyna Nanotech Inc. | Other Health Care | Pre-Seed | $2.3M | 82% |
| Isla Technologies, Inc. | Software / Tech | Seed | $12.2M | 82% |
See where NanoMedical Systems Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at NanoMedical Systems Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.